209 related articles for article (PubMed ID: 14971899)
1. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
3. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.
Cogan PS; Koch TH
J Med Chem; 2003 Nov; 46(24):5258-70. PubMed ID: 14613328
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
6. Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
Cogan PS; Koch TH
J Med Chem; 2004 Nov; 47(23):5690-9. PubMed ID: 15509168
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
8. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro.
Lam HY; Ng PK; Goldenberg GJ; Wong CM
Cancer Treat Rep; 1987 Oct; 71(10):901-6. PubMed ID: 3652053
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Lubczyk V; Bachmann H; Gust R
J Med Chem; 2003 Apr; 46(8):1484-91. PubMed ID: 12672249
[TBL] [Abstract][Full Text] [Related]
12. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
13. Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor.
Lloyd DG; Hughes RB; Zisterer DM; Williams DC; Fattorusso C; Catalanotti B; Campiani G; Meegan MJ
J Med Chem; 2004 Nov; 47(23):5612-5. PubMed ID: 15509159
[TBL] [Abstract][Full Text] [Related]
14. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
Taatjes DJ; Koch TH
Anticancer Res; 1999; 19(2A):1201-8. PubMed ID: 10368676
[TBL] [Abstract][Full Text] [Related]
16. Design and development of water-soluble curcumin conjugates as potential anticancer agents.
Safavy A; Raisch KP; Mantena S; Sanford LL; Sham SW; Krishna NR; Bonner JA
J Med Chem; 2007 Nov; 50(24):6284-8. PubMed ID: 17973470
[TBL] [Abstract][Full Text] [Related]
17. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
18. A convenient synthesis of (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen).
Fauq AH; Maharvi GM; Sinha D
Bioorg Med Chem Lett; 2010 May; 20(10):3036-8. PubMed ID: 20400308
[TBL] [Abstract][Full Text] [Related]
19. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
